ORIGINAL ARTICLES
Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion

https://doi.org/10.1016/S1081-1206(10)62086-8Get rights and content

Background

Antihistamines relieve most seasonal allergic rhinitis (SAR) symptoms, with the exception of nasal congestion, which is often the most troublesome symptom for patients. A nonsedating antihistamine that significantly decreases nasal congestion and improves symptoms of seasonal allergic asthma would be a significant advance in therapy.

Objectives

To evaluate the safety and efficacy of desloratadine 5 mg in patients experiencing moderate SAR, nasal congestion, and symptoms of seasonal allergic asthma.

Methods

This 4-week, multicenter, parallel-group, double-blind study evaluated desloratadine treatment (5 mg once daily) versus placebo in 331 subjects with SAR and mild seasonal allergic asthma. Subjects evaluated SAR and asthma symptoms twice daily, recording 12-hour reflective and instantaneous severity evaluation scores. The primary efficacy parameter was the difference from baseline in am/pm reflective total symptom scores. Changes in individual SAR and asthma symptoms were also analyzed.

Results

Compared with placebo, desloratadine significantly reduced mean am/pm reflective total symptom scores for SAR, beginning with the first dose (P < 0.001) and continuing throughout days 1 to 15 (−4.90 vs −2.98; P < 0.001) and days 1 to 29 (−5.47 vs −3.73; P < 0.001). Desloratadine significantly decreased am/pm reflective total asthma symptom scores for days 1 to 15 (P = 0.023) and am/pm reflective nasal congestion scores over days 1 to 15 and days 1 to 29 (P = 0.006 and P = 0.014, respectively). Desloratadine was safe and well tolerated; adverse events were similar to placebo overall.

Conclusions

Desloratadine provided significant relief from the signs and symptoms of SAR, including nasal congestion. In this patient population, symptoms of seasonal allergic asthma also improved.

REFERENCES (31)

  • WF Schoenwetter

    Allergic rhinitis: epidemiology and natural history

    Allergy Asthma Proc

    (2000)
  • LM DuBuske

    The link between allergy and asthma

    Allergy Asthma Proc

    (1999)
  • J Corren

    The relationship between allergic rhinitis and bronchial asthma

    Curr Opin Pulm Med

    (1999)
  • DK Agrawal et al.

    Desloratadine attenuation of eosinophil chemotaxis, adhesion, and superoxide generation

    Allergy

    (2000)
  • DK Agrawal

    Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug

    Exp Opin Invest Drugs

    (2001)
  • Cited by (98)

    • Diphenhydramine: Time to Move on?

      2022, Journal of Allergy and Clinical Immunology: In Practice
    • Efficacy of non-sedating H1-receptor antihistamines in adults and adolescents with chronic cough: A systematic review

      2021, World Allergy Organization Journal
      Citation Excerpt :

      The crossover trial by Dirksen included 17 patients with moderate asthma and reported that the cough score was lower with loratadine than with placebo, but the difference was not statistically significant (mean difference [MD] ± SD: 0.49 ± 0.19 vs. 0.83 ± 0.22; p > 0.05).31 There were 4 RCTs involving patients with allergic rhinitis and asthma.32,34–36 Since the recent use of inhaled corticosteroids was set as one of the exclusion criteria, the severity of asthma in participants was presumed to be mild in all these trials.

    • Review of Desloratadine Data Using the ARIA Guidelines

      2012, World Allergy Organization Journal
    • Antihistamine Therapy in Allergic Rhinitis

      2011, Immunology and Allergy Clinics of North America
    View all citing articles on Scopus

    Supported by Schering-Plough Research Institute

    View full text